Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Decreases By 18.3%

KALA BIO, Inc. (NASDAQ:KALA) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 21,500 shares, a decline of 18.3% from the November 30th total of 26,300 shares. Based on an average daily volume of 26,200 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.6% of the shares of the company are short sold.

Insider Buying and Selling at KALA BIO

In related news, major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was acquired at an average price of $6.44 per share, for a total transaction of $1,999,999.96. Following the completion of the purchase, the insider now directly owns 1,083,398 shares of the company’s stock, valued at $6,977,083.12. This trade represents a 40.18 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.32% of the stock is currently owned by company insiders.

Institutional Trading of KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP acquired a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest position. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent SEC filing. 24.61% of the stock is currently owned by institutional investors and hedge funds.

KALA BIO Price Performance

KALA traded up $0.07 on Tuesday, hitting $6.94. 30,129 shares of the company were exchanged, compared to its average volume of 77,429. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. The business’s fifty day moving average is $6.60 and its 200 day moving average is $6.24. The firm has a market capitalization of $31.99 million, a P/E ratio of -0.56 and a beta of -2.15. KALA BIO has a fifty-two week low of $4.21 and a fifty-two week high of $9.25.

KALA BIO (NASDAQ:KALA) last released its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. As a group, sell-side analysts anticipate that KALA BIO will post -10.84 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a research note on Friday, November 15th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.